Skip to main content
Top
Published in: Internal and Emergency Medicine 1/2011

01-02-2011 | IM - Commentary

An emerging problem in clinical practice: how to treat chronic headache patients

Author: Luigi Alberto Pini

Published in: Internal and Emergency Medicine | Issue 1/2011

Login to get access

Excerpt

In this issue, an interesting article by Farinelli and co-workers [1] debates an important emerging and not yet resolved problem: how to treat the chronic headaches complicated by medication overuse. Headache is the most common neurological disease in clinical practice. In Europe, this affects about 51% of the population, of which 31% are tension-type headache and 14% are migraine sufferers; 2% of these patients become chronic sufferers, more than 15/day/month, and chronic daily headache (CDH). 4–5% of general population suffers from a chronic form (CDH), with prevalence between 1.7 and 2.1% in men and between 2.8 and 6.8% in women [2]; within this group of patients in the US general population ranges around 1.3–2% of chronic migraine (CM). …
Literature
1.
go back to reference Farinelli I, Dionisi I, Martelletti P (2010) Rehabilitating chronic migraine complicated by medication overuse headaches: how can we prevent migraine relapse? Intern Emerg Med. doi:10.1007/s11739-010-0410-9 Farinelli I, Dionisi I, Martelletti P (2010) Rehabilitating chronic migraine complicated by medication overuse headaches: how can we prevent migraine relapse? Intern Emerg Med. doi:10.​1007/​s11739-010-0410-9
2.
go back to reference Stovner LJ, Zwart JA, Hagen K, Terwindt GM, Pascual J (2006) Epidemiology of headache in Europe. Eur J Neurol 13:333–345CrossRefPubMed Stovner LJ, Zwart JA, Hagen K, Terwindt GM, Pascual J (2006) Epidemiology of headache in Europe. Eur J Neurol 13:333–345CrossRefPubMed
3.
go back to reference Harris JA, Corsi M, Quartaroli M, Arban R, Bentivoglio M (1996) Upregulation of spinal glutamate receptors in chronic pain. Neuroscience 74:7–12CrossRefPubMed Harris JA, Corsi M, Quartaroli M, Arban R, Bentivoglio M (1996) Upregulation of spinal glutamate receptors in chronic pain. Neuroscience 74:7–12CrossRefPubMed
4.
go back to reference Coderre TJ, Yashpal K (1994) Intracellular messengers contributing to persistent nociception and hyperalgesia induced by l-glutamate and substance P in the rat formalin pain model. Eur J Neurosci 6:1328–1334CrossRefPubMed Coderre TJ, Yashpal K (1994) Intracellular messengers contributing to persistent nociception and hyperalgesia induced by l-glutamate and substance P in the rat formalin pain model. Eur J Neurosci 6:1328–1334CrossRefPubMed
5.
go back to reference Gallai V, Alberti A, Gallai B, Coppola F, Floridi A, Sarchielli P (2003) Glutamate and nitric oxide pathway in chronic daily headache: evidence from cerebrospinal fluid. Cephalalgia 23:166–174CrossRefPubMed Gallai V, Alberti A, Gallai B, Coppola F, Floridi A, Sarchielli P (2003) Glutamate and nitric oxide pathway in chronic daily headache: evidence from cerebrospinal fluid. Cephalalgia 23:166–174CrossRefPubMed
6.
go back to reference Lovell BV, Marmura MJ (2010) New therapeutic developments in chronic migraine. Curr Opinion Neurol 23:254–258CrossRef Lovell BV, Marmura MJ (2010) New therapeutic developments in chronic migraine. Curr Opinion Neurol 23:254–258CrossRef
7.
go back to reference Mathew NT, Jaffri SF (2009) A double-blind comparison of onabotulinumtoxin (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache 49:1466–1478CrossRefPubMed Mathew NT, Jaffri SF (2009) A double-blind comparison of onabotulinumtoxin (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache 49:1466–1478CrossRefPubMed
8.
go back to reference Rossi P, Jensen R, Nappi G et al (2009) A narrative review on the management of medication-overuse headache: the steep road from experience to evidence. J Headache Pain 10:407–417CrossRefPubMed Rossi P, Jensen R, Nappi G et al (2009) A narrative review on the management of medication-overuse headache: the steep road from experience to evidence. J Headache Pain 10:407–417CrossRefPubMed
9.
go back to reference Simmaco M, Borro M, Missori S, Martelletti P (2009) Pharmacogenomics in migraine: catching biomarkers for a predictable disease control. Exp Rev Neurother 9:1267–1269CrossRef Simmaco M, Borro M, Missori S, Martelletti P (2009) Pharmacogenomics in migraine: catching biomarkers for a predictable disease control. Exp Rev Neurother 9:1267–1269CrossRef
10.
go back to reference Trucco M, Meineri P, Ruiz L, Gionco M (2010) On behalf of the “Gruppo Neurologico Ospedaliero Interregionale per lo Studio delle Cefalee” Medication-Overuse Headache: Withdrawal and Prophylactic Therapeutic Regimen. Headache 50:989–997CrossRefPubMed Trucco M, Meineri P, Ruiz L, Gionco M (2010) On behalf of the “Gruppo Neurologico Ospedaliero Interregionale per lo Studio delle Cefalee” Medication-Overuse Headache: Withdrawal and Prophylactic Therapeutic Regimen. Headache 50:989–997CrossRefPubMed
11.
go back to reference Archibald N, Lipscomb J and McCrory DC (1999) Resource utilization and costs of care for treatment of chronic headache. Agency for Health Care Policy and Research (US); PMID: 20734516 Archibald N, Lipscomb J and McCrory DC (1999) Resource utilization and costs of care for treatment of chronic headache. Agency for Health Care Policy and Research (US); PMID: 20734516
Metadata
Title
An emerging problem in clinical practice: how to treat chronic headache patients
Author
Luigi Alberto Pini
Publication date
01-02-2011
Publisher
Springer Milan
Published in
Internal and Emergency Medicine / Issue 1/2011
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-010-0484-4

Other articles of this Issue 1/2011

Internal and Emergency Medicine 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine